Skip to Main Content
Contribute Try STAT+ Today

After a year of deliberation, the Food and Drug Administration released final guidelines for penalizing clinical trial sponsors that fail to register studies, do not report results to a government database, or submit false information. But transparency experts argued the agency effort falls short in some ways.

The guidance, which notes any company or university that does not provide required information to may face a $10,000 fine for each infraction, comes after a long-running effort to push the FDA to penalize violators.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.